NetraMark Holdings Inc. announces that it has signed a NetraAI Lab contract with a pharmaceutical company (the "Sponsor") to use NetraAI to analyze Phase 2 clinical trial data and deliver key insights and testable hypotheses with the potential to de-risk further development of the Sponsor's asset. Under the scope of this project, the Sponsor has provided NetraMark with data from patients who participated in a completed Phase 2 clinical trial of a specific therapy and NetraMark applied its proprietary NetraAI clinical solution to the data to achieve five key objectives: characterizing the drivers of placebo and treatment responses; feature significance testing; extracting personas that characterize placebo responders/treatment non-responders (PRTNR) and placebo non-responders/treatment responders (PNRTR); creating probability density distribution maps of key factors across all patients in placebo and treatment arms, in order to enable enrichment criteria for future trials; and establishing a data environment that enables continued exploration of the data. NetraMark will identify key inclusion /exclusion criteria that are predicted with high statistical confidence.

Use of these criteria in future trials is expected to increase the number of PNRTR subjects while reducing the number of PRTNR subjects, enabling the trial to potentially demonstrate significant efficacy in a smaller, better-defined patient population.